Magnetic Fields Cancer Research Results

MF, Magnetic Fields: Click to Expand ⟱
Features: Therapy
Magnetic Fields can be Static, or pulsed. The most common therapy is a pulsed magnetic field in the uT or mT range.
The main pathways affected are:
Calcium Signaling: -influence the activity of voltage-gated calcium channels.
Oxidative Stress and Reactive Oxygen Species (ROS) Pathways
Heat Shock Proteins (HSPs) and Cellular Stress Responses
Cell Proliferation and Growth Signaling: MAPK/ERK pathway.
Gene Expression and Epigenetic Modifications: NF-κB
Angiogenesis Pathways: VEGF (improving VEGF for normal cells)
PEMF was found to have a 2-fold increase in drug uptake compared to traditional electrochemotherapy in rat melanoma models

Pathways:
- most reports have ROS production increasing in cancer cells , while decreasing in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, VEGF↓(mostly regulated up in normal cells),
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, GLUT1↓, LDH↓, HK2↓, PFKs↓, PDKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, cytoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Non-Static Magnetic Fields (AC / Pulsed / Oscillating MF)
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Reactive oxygen species (ROS) ↑ ROS (P→R); often sustained (G) ↑ ROS (P); ↔/↓ net ROS (R→G) P, R, G Upstream redox perturbation MF perturbs electron/radical dynamics: normal cells often adapt (ROS setpoint ↓), cancer cells less so
2 NRF2 antioxidant response ↔ / insufficient NRF2 induction (R→G) ↑ NRF2 activation (R→G) R, G Adaptive redox defense Explains mixed ROS direction in normal cells (initial ↑ then adaptive ↓)
3 Glutathione (GSH) homeostasis ↓ GSH (R→G) ↔ or transient ↓ (R) with recovery (G) R, G Redox buffering capacity GSH depletion reflects sustained oxidative load; recovery indicates successful adaptation
4 Superoxide dismutase (SOD) / antioxidant enzymes ↔ or inadequate enzyme upshift (G) ↑ SOD/GPx/CAT capacity (G) G Longer-term antioxidant remodeling Often the “endpoint” readout that correlates with ROS-normalization in normal tissue
5 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak (P→R) ↔ mild, reversible ETC perturbation (P→R) P, R Bioenergetic destabilization ETC perturbation is a mechanistic bridge between MF exposure and ROS/ΔΨm changes
6 Mitochondrial membrane potential (ΔΨm / MMP) ↓ ΔΨm (R); may progress (G) ↔ preserved or reversible dip (R) R, G Mitochondrial dysfunction thresholding ΔΨm loss typically follows ROS/ETC disruption rather than preceding it
7 Ca²⁺ signaling (VGCC / ER–mitochondria Ca²⁺ flux) ↑ dysregulated Ca²⁺ influx/transfer (P→R); overload may persist (G) ↑ transient Ca²⁺ signaling (P); homeostasis restored (R→G) P, R, G Stress signal amplification Ca²⁺ dysregulation links ROS/ETC perturbation to ER stress and mitochondrial dysfunction (amplifies ΔΨm loss and UPR commitment)
8 Mitochondrial permeability transition pore (MPTP) ↑ MPTP opening propensity (R); sustained opening possible (G) ↔ transient or closed (R→G) P, R, G Commitment point for mitochondrial failure MPTP opening integrates ROS, Ca²⁺ overload, and ΔΨm loss; acts as a threshold event converting reversible stress into irreversible mitochondrial dysfunction
9 ER stress / UPR ↑ ER stress (R); CHOP-commitment possible (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis stress Often downstream of ROS + Ca²⁺ handling perturbations
10 DNA damage (oxidative) ↑ damage markers (R→G) ↔ or repaired (G) R, G Checkpoint pressure Generally secondary to ROS; interpret as stress consequence not “direct genotoxicity”
11 LDH / glycolytic flux ↓ glycolytic performance (R→G) ↔ flexible substrate switching (R→G) R, G Metabolic vulnerability Redox imbalance can destabilize high-rate glycolysis in cancer-biased contexts
12 Thioredoxin system (Trx / TrxR) ↓ functional reserve / overload (R→G) ↔ preserved capacity (G) R, G Parallel antioxidant system stress Useful when GSH-only does not explain redox phenotype
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


Scientific Papers found: Click to Expand⟱
514- MF,    Therapeutic electromagnetic field effects on angiogenesis and tumor growth
- in-vivo, NA, NA
TumVol↓,
513- MF,    Exposure to a specific time-varying electromagnetic field inhibits cell proliferation via cAMP and ERK signaling in cancer cells
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, MCF-7 - in-vivo, Pca, HeLa
TumCG↓, p‑ERK↑, cAMP⇅,
512- MF,    Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells
- in-vitro, BC, MCF-7 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, FF95
TumCP↓, *toxicity↓, ChemoSen↑, RadioS↑, selectivity↑, Ca+2↑,
511- MF,    Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor growth and vascularity
- in-vivo, NA, NA
TumVol↓,
510- MF,    Effect of a 9 mT pulsed magnetic field on C3H/Bi female mice with mammary carcinoma. A comparison between the 12 Hz and the 460 Hz frequencies
- in-vivo, NA, NA
OS↑,
509- MF,    Is extremely low frequency pulsed electromagnetic fields applicable to gliomas? A literature review of the underlying mechanisms and application of extremely low frequency pulsed electromagnetic fields
- Review, NA, NA
Ca+2↑, TumAuto↑, Apoptosis↑, angioG↓, ROS↑,
508- MF,  doxoR,    Synergistic cytotoxic effects of an extremely low-frequency electromagnetic field with doxorubicin on MCF-7 cell line
- in-vitro, BC, MCF-7
ROS↑, Apoptosis↑, TumCCA↑,
506- MF,  doxoR,    Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells
- in-vitro, OS, LM8
TumCP↓, p‑CHK1↓, Ca+2↑, Casp3↓, Casp7↓, p‑BAD↓, ChemoSen↑,
505- MF,    Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach
- Case Report, NA, NA
Pain↓, OS↑,
504- MF,    Effect of Magnetic Fields on Tumor Growth and Viability
- in-vivo, NA, NA
TumCG↓,
503- MF,    Effects of acute and chronic low frequency electromagnetic field exposure on PC12 cells during neuronal differentiation
- in-vitro, NA, PC12
ROS↑, Ca+2↑,
507- MF,    Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism
- in-vitro, Liver, HepG2 - in-vitro, Lung, A549 - in-vitro, Nor, GP-293
MMP↓, TumCG↓, ROS↑, *Ca+2↓, Ca+2↑, selectivity↑, i-pH↑,
500- MF,    Anti-Oxidative and Immune Regulatory Responses of THP-1 and PBMC to Pulsed EMF Are Field-Strength Dependent
- in-vitro, AML, THP1
ROS↑, Prx6↑, DHCR24↑, IL10↑,
502- MF,    Electromagnetic field investigation on different cancer cell lines
- in-vitro, BC, MDA-MB-231 - in-vitro, Colon, SW480 - in-vitro, CRC, HCT116
TumCG↓, Apoptosis↑,
4103- MF,    Comparing the Effects of Long-term Exposure to Extremely Low-frequency Electromagnetic Fields With Different Values on Learning, Memory, Anxiety, and β-amyloid Deposition in Adult Rats
- in-vivo, NA, NA
*Dose↝, *memory↑, *ROS↑, *MDA↑,
4120- MF,    Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer's Disease
- Human, AD, NA
*memory↑,
4119- MF,    Therapeutic potential and mechanisms of repetitive transcranial magnetic stimulation in Alzheimer’s disease: a literature review
- Review, AD, NA
*cognitive↑, *memory↑, *motorD↑, *eff↑, *eff↑, *Dose↝, *Dose↝, *Dose↝, *BDNF↑, *Aβ↓, *eff↑,
4118- MF,    Effects of transcranial magnetic stimulation on neurobiological changes in Alzheimer's disease
- Review, AD, NA
*cognitive↑, *BDNF↑, *neuroP↑, *memory↑, *ROS↓, *antiOx↑, *Aβ↓, *eff↑,
4117- MF,    Pulsed electromagnetic fields improve the healing process of Achilles tendinopathy: a pilot study in a rat model
- in-vivo, NA, NA
*other↑,
4116- MF,    Low‑frequency pulsed electromagnetic field promotes functional recovery, reduces inflammation and oxidative stress, and enhances HSP70 expression following spinal cord injury
- in-vivo, NA, NA
*Inflam↓, *TNF-α↓, *IL1β↓, *iNOS↓, *ROS↓, *Catalase↑, *SOD↑, HSP70/HSPA5↑,
4112- MF,    Novel protective effects of pulsed electromagnetic field ischemia/reperfusion injury rats
- in-vivo, Stroke, NA
*cardioP↑, *Bcl-2↑, *BAX↓, *ROS↓,
4111- MF,    Coupling of pulsed electromagnetic fields (PEMF) therapy to molecular grounds of the cell
- Review, Arthritis, NA
*Inflam↓, *Cartilage↑, *Pain↓, *QoL↑, *Dose↝, *VEGF↑, *NO↑, *TGF-β↑, *MMP9↓, *PGE2↑, *GPx3↑, *SOD2↑, *Catalase↑, *GSR↑, *Ca+2↑,
4110- MF,    Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia
- Review, Stroke, NA
*ROS↓, *Inflam↓, *other↝, *neuroP↑, *Apoptosis↓, *Hif1a↝,
4109- MF,    Overexpression of miR-26b-5p regulates the cell cycle by targeting CCND2 in GC-2 cells under exposure to extremely low frequency electromagnetic fields
- in-vitro, NA, NA
*other↝,
4106- MF,    Cognitive Decline: Current Intervention Strategies and Integrative Therapeutic Approaches for Alzheimer's Disease
- Review, AD, NA
*cognitive↑, *memory↑, *Aβ↓, *neuroP↑,
4105- MF,    Extremely low frequency electromagnetic fields stimulation modulates autoimmunity and immune responses: a possible immuno-modulatory therapeutic effect in neurodegenerative diseases
- Review, AD, NA
*Inflam↓, *neuroP↑, *NO↑, *ROS↓, *NO↓, *MCP1↑, *HSP70/HSPA5↑, *antiOx↑, *NRF2↑, *NF-kB↓,
4104- MF,    Effects of exposure to extremely low-frequency electromagnetic fields on spatial and passive avoidance learning and memory, anxiety-like behavior and oxidative stress in male rats
- in-vivo, NA, NA
*memory↑, *ROS↑,
4146- MF,    Pulsed electromagnetic field enhances brain-derived neurotrophic factor expression through L-type voltage-gated calcium channel- and Erk-dependent signaling pathways in neonatal rat dorsal root ganglion neurons
- in-vivo, AD, NA
*BDNF↑, *ERK↑,
4102- MF,    Modulation of antioxidant enzyme gene expression by extremely low frequency electromagnetic field in post-stroke patients
- Human, Stroke, NA
*Catalase↑, *SOD1↑, *SOD2↑, *GPx1↑, *GPx4↑, *Dose↝,
4101- MF,    Benign Effect of Extremely Low-Frequency Electromagnetic Field on Brain Plasticity Assessed by Nitric Oxide Metabolism during Poststroke Rehabilitation
- Human, Stroke, NA
*motorD↑, *cognitive↑, *eff↑, *NO↑, *other↝, *neuroP↑,
4100- MF,    Neurobiological effects and mechanisms of magnetic fields: a review from 2000 to 2023
- Review, Var, NA
*memory↑, *Mood⇅,
4099- MF,    Extremely low frequency electromagnetic field reduces oxidative stress during the rehabilitation of post-acute stroke patients
- Trial, Stroke, NA
*ROS↓,
4098- MF,    Extremely low frequency electromagnetic field (ELF-EMF) reduces oxidative stress and improves functional and psychological status in ischemic stroke patients
- Trial, Stroke, NA
*antiOx↑, *cognitive↑, *Dose↝,
4097- MF,    Theta Frequency Electromagnetic Stimulation Enhances Functional Recovery After Stroke
- Trial, Stroke, NA
*motorD↑, *eff↑, *Dose↝,
4096- MF,    Extremely Low‐Frequency and Low‐Intensity Electromagnetic Field Technology (ELF‐EMF) Sculpts Microtubules
- in-vitro, AD, NA
*p‑tau↓, *neuroP↑, *Dose↝,
4095- MF,    Frequency-tuned electromagnetic field therapy improves post-stroke motor function: A pilot randomized controlled trial
- Trial, Stroke, NA
*Dose↝, *motorD↑,
4094- MF,    EMAGINE-Study protocol of a randomized controlled trial for determining the efficacy of a frequency tuned electromagnetic field treatment in facilitating recovery within the subacute phase following ischemic stroke
- Study, Stroke, NA
*neuroP↑, *Dose↝,
4093- MF,    Low-intensity electromagnetic fields induce human cryptochrome to modulate intracellular reactive oxygen species
- in-vivo, NA, NA
*ROS↑, *eff↑,
4092- MF,    Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology
- Review, Var, NA
Apoptosis↑, selectivity↑, ROS↑, Catalase↓, TumVol↓, angioG↓,
4356- MF,    Pulsed electromagnetic fields synergize with graphene to enhance dental pulp stem cell-derived neurogenesis by selectively targeting TRPC1 channels
- in-vitro, Nor, NA
*Diff↑, *TRPC1↑, *ROS↑,
5534- MF,    Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps
- vitro+vivo, BC, MDA-MB-231 - in-vitro, Nor, MCF10
TumVol↓, VGSC↑, OS↑, selectivity↑, eff↑,
5533- MF,    Magnetic field-induced drug permeability in liposome vesicles
- in-vitro, Nor, NA
*Dose↝, *CellMemb↑, *other↝,
5532- MF,    Magnetoporation: New Method for Permeabilization of Cancerous Cells to Hydrophilic Drugs
- in-vivo, BC, NA
Dose↑, CellMemb↑, eff↝, other↝, TumCG↓,
5531- MF,    Effect of low frequency, low amplitude magnetic fields on the permeability of cationic liposomes entrapping carbonic anhydrase: I. Evidence for charged lipid involvement
- in-vitro, NA, NA
Dose↝, CellMemb↑,
5247- MF,    Anticancer Activity by Magnetic Fields: Inhibition of Metastatic Spread and Growth in a Breast Cancer Model
- in-vivo, BC, MDA-MB-468
TumCI↓,
5246- MF,  Chemo,    Non-ionizing Electromagnetic Radiation: A Study of Carcinogenic and Cancer Treatment Potential
- in-vitro, BC, MCF-7
ChemoSen↑,
5241- MF,    A review on the use of magnetic fields and ultrasound for non-invasive cancer treatment
- Review, Var, NA
other↑, BloodF↑, Glycolysis↓, ATP↓, VEGF↓, ROS↑, P-gp↓, Apoptosis↑, selectivity↑, Ca+2↑, Catalase↑,
5240- MF,    Effect of low frequency magnetic fields on the growth of MNP-treated HT29 colon cancer cells
- in-vitro, Colon, HT29
TumCP⇅,
4571- MF,    Magnetic Fields and Reactive Oxygen Species
- Review, NA, NA
*ROS⇅, *ETC↓, Dose↝, Dose↝,
4568- MF,    Extremely low-frequency pulses of faint magnetic field induce mitophagy to rejuvenate mitochondria
- Study, NA, NA
*ETC↓, *OCR↑, *MMP↑, *ROS⇅, *MMP⇅,

Showing Research Papers: 101 to 150 of 262
Prev Page 3 of 6 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 262

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

Catalase↓, 1,   Catalase↑, 1,   Prx6↑, 1,   ROS↑, 7,  

Mitochondria & Bioenergetics

ATP↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis

cAMP⇅, 1,   DHCR24↑, 1,   Glycolysis↓, 1,  

Cell Death

Apoptosis↑, 5,   p‑BAD↓, 1,   Casp3↓, 1,   Casp7↓, 1,  

Transcription & Epigenetics

other↑, 1,   other↝, 1,  

Protein Folding & ER Stress

HSP70/HSPA5↑, 1,  

Autophagy & Lysosomes

TumAuto↑, 1,  

DNA Damage & Repair

p‑CHK1↓, 1,  

Cell Cycle & Senescence

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

p‑ERK↑, 1,   TumCG↓, 5,   VGSC↑, 1,  

Migration

Ca+2↑, 6,   TumCI↓, 1,   TumCP↓, 2,   TumCP⇅, 1,  

Angiogenesis & Vasculature

angioG↓, 2,   VEGF↓, 1,  

Barriers & Transport

CellMemb↑, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling

IL10↑, 1,  

Cellular Microenvironment

i-pH↑, 1,  

Drug Metabolism & Resistance

ChemoSen↑, 3,   Dose↑, 1,   Dose↝, 3,   eff↑, 1,   eff↝, 1,   RadioS↑, 1,   selectivity↑, 5,  

Clinical Biomarkers

BloodF↑, 1,  

Functional Outcomes

OS↑, 3,   Pain↓, 1,   TumVol↓, 4,  
Total Targets: 43

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

antiOx↑, 3,   Catalase↑, 3,   GPx1↑, 1,   GPx3↑, 1,   GPx4↑, 1,   GSR↑, 1,   MDA↑, 1,   NRF2↑, 1,   ROS↓, 6,   ROS↑, 4,   ROS⇅, 2,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 2,  

Mitochondria & Bioenergetics

ETC↓, 2,   MMP↑, 1,   MMP⇅, 1,   OCR↑, 1,  

Cell Death

Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   iNOS↓, 1,  

Transcription & Epigenetics

other↑, 1,   other↝, 4,  

Protein Folding & ER Stress

HSP70/HSPA5↑, 1,  

Proliferation, Differentiation & Cell State

Diff↑, 1,   ERK↑, 1,  

Migration

Ca+2↓, 1,   Ca+2↑, 1,   Cartilage↑, 1,   MMP9↓, 1,   TGF-β↑, 1,   TRPC1↑, 1,  

Angiogenesis & Vasculature

Hif1a↝, 1,   NO↓, 1,   NO↑, 3,   VEGF↑, 1,  

Barriers & Transport

CellMemb↑, 1,  

Immune & Inflammatory Signaling

IL1β↓, 1,   Inflam↓, 4,   MCP1↑, 1,   NF-kB↓, 1,   PGE2↑, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission

BDNF↑, 3,   p‑tau↓, 1,  

Protein Aggregation

Aβ↓, 3,  

Drug Metabolism & Resistance

Dose↝, 12,   eff↑, 7,  

Functional Outcomes

cardioP↑, 1,   cognitive↑, 5,   memory↑, 7,   Mood⇅, 1,   motorD↑, 4,   neuroP↑, 7,   Pain↓, 1,   QoL↑, 1,   toxicity↓, 1,  
Total Targets: 58

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:172  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page